IL-13Rα2 CARs Enhancing Solid Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR-T cell therapies show limited activity in treating solid cancers due to inadequate targeting of IL-13Rα2, a tumor antigen overexpressed in various cancers, highlighting the need for improved immunotherapeutic strategies.
Innovation Solution
Development of chimeric antigen receptors (CARs) specifically targeting IL-13Rα2, comprising a single chain fragment variable (scFv) that binds IL-13Rα2, a hinge domain, a transmembrane domain, and intracellular signaling domains, which are encoded by nucleic acids and expressed in immune cells like T cells, enabling targeted cancer therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CAR-T cell therapy is used for solid cancers, then the treatment approach follows standard immunotherapy protocols, but the targeting specificity and efficacy against IL-13Rα2 are insufficient
Solution Approach 1:
The patent applies local quality by designing a CAR construct with specialized components tailored for solid tumor targeting. The scFv domain is specifically engineered to recognize IL-13Rα2 with high affinity, while the hinge and transmembrane domains are optimized for solid tumor microenvironment penetration. This localized optimization of specific CAR components addresses the insufficient targeting efficacy without requiring complete redesign of the entire CAR-T system.
Solution Approach 2:
The invention employs composite materials by creating a chimeric antigen receptor that integrates multiple functional domains from different sources. The CAR construct combines the scFv binding domain, hinge region, transmembrane domain, and intracellular signaling domains into a single composite molecule. This composite structure enables simultaneous achievement of specific antigen recognition, proper membrane positioning, and effective signal transduction, thereby improving both reliability and adaptability for solid cancer therapy.
2Measurement precision
If CARs with high targeting specificity are developed, then recognition of IL-13Rα2 is improved, but the complexity of CAR construction and implementation increases
Solution Approach 1:
The patent applies segmentation by dividing the CAR construct into distinct functional modules: the scFv domain for antigen binding, the hinge domain for flexibility, the transmembrane domain for membrane anchoring, and the intracellular domain for signal transduction. This modular segmentation allows for systematic optimization of each component's specificity while managing overall construction complexity through standardized assembly protocols.
Solution Approach 2:
The invention utilizes universality by designing a CAR construct that performs multiple functions within a single molecular framework. The same CAR structure provides antigen recognition, cell membrane integration, and immune activation capabilities. This multi-functionality reduces the need for separate specialized components, thereby improving measurement precision while controlling device complexity through a unified design approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IL-13Rα2-targeting CARs enhance the specificity and efficacy of immune cells in recognizing and attacking cancer cells overexpressing IL-13Rα2, potentially leading to improved treatment outcomes for solid tumors.
Implementation Method 1
the scFv specifically binds IL-13Rα2
Data Source
AI summary
Immunotherapies, particularly chimeric antigen receptors targeting IL-13Rα2 and their use for treating cancer are provided. A single chain fragment variable (scFv) that specifically binds IL-13Rα2, chimeric antigen receptors (CARs) including the IL-13Rα2 scFv, nucleic acids encoding the CARs, vectors including the nucleic acids encoding the CARs, and immune cells expressing the CARs are provided. Also provided are methods of treating a subject with cancer, including administering to the subject an immune cell expressing an IL-13Rα2 scFv-CAR alone or in combination with other cancer therapies.